Sanguinarine: A Novel Agent Against Prostate Cancer
Abstract
The traditional surgery and therapy has not been successful in the management of prostate cancer (CaP). Therefore, the search for novel agents and approaches for the treatment of CaP continues. Natural plant-based products have shown promise as anticancer agents. Sanguinarine, a benzophenanthridine alkaloid derived from the root of Sanguinaria Canadensis, has been shown to possess anti-microbial, antioxidant and anti-inflammatory properties. Our earlier studies suggested that sanguinarine may be developed as an agent for the management of prostate cancer. Based on this rationale, funded by the DOD (Award - W81XWH-04-1-0220), we initiated a study to investigate the hypothesis that sanguinarine will impart antiproliferative effects against prostate cancer via a modulation in NF-kB-pathwaymediated apoptosis. In the current reporting period (01/16/2005 01/15/2006) we have made significant advancement. The key accomplishments for this reporting period are as follows. We have demonstrated that sanguinarine possesses chemopreventive/antiproliferative effects against prostate cancer in an athymic nude mice xenograft model. Further, our data suggested that sanguinarine-caused effects are mediated via modulations in NF-kB pathway and cyclin kinase inhibitor-cyclin-cyclin dependent kinase machinery. In addition, our pilot study has shown that transgenic TRAMP model, which mimics human disease, is suitable for chemoprevention/intervention studies with
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 01, 2006
- Accession Number
- ADA452511
Entities
People
- Nihal Ahmad
Organizations
- University of Wisconsin–Madison